Articles
Bionomics boon from R&D Tax Incentive
Bionomics (ASX:BNO) expects a larger-than-expected $4.2 million R&D tax incentive rebate for FY12, and will be now able to claim foreign expenditures under the program. [ + ]
Australian bid wins international agricultural biotechnology conference
Australia has won the bid to host the 2015 Agricultural Biotechnology International Conference (ABIC), the world’s leading forum for the promotion of innovation in agricultural bioscience. [ + ]
Three blind mice no longer
Have you ever seen such a thing in your life as three blind mice having cells transplanted into their eyes, reforming and helping them regain their sight? Researchers from the University of Oxford have seen exactly that. [ + ]
Phenotype MicroArray technology making breakthrough discoveries on tuberculosis bacterium
In a paper recently published in the journal PLOS ONE, a research team reported breakthrough progress in understanding the metabolic and phenotypic properties of the bacterium Mycobacterium tuberculosis and its close relative Mycobacterium bovis. The publication shows that Biolog’s Phenotype MicroArray (PM) technology allows these bacteria to be studied much more quickly and easily, which will accelerate the pace of mycobacterial research. [ + ]
Mesoblast to head to phase III for stem cell treatment for spinal fusion
Positive phase II results for Mesoblast’s (ASX:MSB) stem cell treatment for spinal fusion have prompted the company to look at moving to phase III this year. [ + ]
Productivity Commission releases draft report on compulsory licensing of patents
After reviewing the compulsory licensing provisions in the patents system, the Productivity Commission has released a draft report, which is now open for comment until 8 February 2013. [ + ]
Allied Healthcare explores new tissue engineering applications
A study has shown Allied Healthcare’s (ASX:AHZ) tissue engineering technology has potential applications in hernia repair and pelvic floor reconstruction. [ + ]
Sirtex yet to peak: Wong
Sirtex Medical (ASX:SRX) CEO Gilman Wong is confident the company will continue to grow at a similar rate to the last five years, with it announcing its 34th consecutive quarter of growth. [ + ]
A temperature below absolute zero
Atoms at negative absolute temperature are the hottest systems in the world. [ + ]
Invion repurposes blood pressure drug to target asthma
Nadolol is known for its role in treating blood pressure, but now Invion is conducting a phase II trial to assess its effects on asthma and chronic bronchitis. [ + ]
Abbott spins-off pharmaceutical division into AbbVie
Abbott Laboratories is now two companies, with it spinning-off its pharmaceutical business into a new company, AbbVie. [ + ]
Sirtex shines as biotech gears up for big year
As the year commences, Sirtex Medical is being hailed a stand-out performer for 2012 and some analysts are tipping the biotech sector to be a “hot space” in 2013. [ + ]
Bioniche wraps up with Endo, forges path for Urocidin
After reclaiming the rights to its bladder cancer treatment, Urocidin, Bioniche (ASX:BNC) is now considering seeking approval in the Canadian market. [ + ]
How the kilogram has put on weight
Post-Christmas and most of us are feeling the overindulgence. But take heart - experts at Newcastle University, UK, have shown even the kilogram itself has put on weight. [ + ]
Growing tumours grows hope for children with cancer
Diffuse Pontine Glioma (DIPG) may not be particularly well known, but according to oncologist Dr David Ziegler, it is “one of the most common and the most aggressive brain tumours we see in kids”. Now, Dr Ziegler and colleagues from the Children’s Cancer Institute of Australia (CCIA) have set out to grow their own tumours in the institute’s ACRF Drug Discovery Centre. [ + ]
